-
Uncategorized1 week ago
Lilly Grows AI Footprint with Up-to-$2.75B Insilico Collaboration
Eli Lilly and Insilico Medicine are expanding a three-year partnership with a discovery and development collaboration that could generate more than $2.75 billion for the AI-based drug developer, Insilico said Sunday. Lilly has agreed...
-
Uncategorized1 week ago
#AAD26: Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcoma
Sanofi on Saturday shared more mixed efficacy results from a Phase 3 atopic dermatitis program for its anti-OX40 ligand monoclonal antibody, further eroding Wall Street’s already...
-
Uncategorized1 week ago
African Trypanosomes Use a Molecular Shredder to Avoid Detection in the Bloodstream
In mammalian hosts, the African trypanosome parasite replicates freely in the bloodstream, despite being fully exposed to the immune system. To do this, the pathogen relies...
-
Uncategorized1 week ago
Trustworthy AI in clinical oversight
AI can accelerate clinical work and preserve traceability, but only if users can trust it. Read More
-
Uncategorized1 week ago
6 FDA Decisions To Watch in Q2 2026
6 FDA Decisions To Watch in Q2 2026
-
Uncategorized1 week ago
Common Pitfalls That Delay Regulatory Submissions, and How to Prevent Them
Common Pitfalls That Delay Regulatory Submissions, and How to Prevent Them
-
Uncategorized1 week ago
Lilly, Baseline Investigate GLP-1s’ Potential in Substance Use as Interest Mounts
Accumulating scientific evidence and industry interest from Eli Lilly, Altimmune and startup Baseline Therapeutics is driving further research on the therapeutic potential of GLP-1 receptor agonists...
-
Uncategorized1 week ago
Kailera plots IPO to fund obesity pipeline after one of the biggest raises of 2025
Kailera Therapeutics—one of the biggest money-raisers of 2025—is now seeking to go public as it seeks further funding to push its obesity portfolio through the clinic.Read...
-
Uncategorized1 week ago
StockWatch: Wave Plummets 50% on Obesity Data
Disappointed investors punished Wave Life Sciences (NASDAQ: WVE), causing its shares to lose roughly half their value on Thursday after the RNA-based drug developer reported mixed...
-
Uncategorized1 week ago
Engineering macrophage-targeted trispecific immune cell engagers for tumor immunotherapy
Nature Biotechnology, Published online: 30 March 2026; doi:10.1038/s41587-026-03104-5 Immune cell engagers (ICEs) have emerged as a promising strategy for cancer immunotherapy, but their efficacy in solid...
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
